Dermavant’s Vtama Performs Well in Phase 3 AD Studies; New Data Paves Way for Upcoming sNDA Submission
Fully 80.7% of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI ) 75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Vtama cream is a novel, aryl hydrocarbon receptor agonist in development as a once-daily, steroid-free, topical cream for both acute treatment and long-term management of AD. […]